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Background: Renal replacement therapy may have a favorable effect on diastolic left ventricular function, but it is
not clear whether hemodiafiltration is superior to hemodialysis in this field. Nitric oxide (NO) and asymmetric
dimethylarginine (ADMA) may play a role in the changes of intracardiac hemodynamics, but it is not clear whether
the different renal replacement methods have disparate influence on the metabolism of these materials.
Methods: Thirty patients on renal replacement therapy were investigated. First, data was analyzed while patients
received hemodiafiltration over a period of three months. Then, the same patients were evaluated during treatment
with hemodialysis for at least another three months. Echocardiography was performed before and after renal
replacement therapy.
Results: No significant difference was found in the volume removals between hemodialysis and hemodiafiltration.
The left atrial diameter and transmitral flow velocities (E/A) decreased significantly only during hemodiafiltration.
A positive correlation was observed between the left atrial diameter and E/Ea representing the left ventricular
pressure load during hemodiafiltration. Significant correlations between NO and A and E/A were observed only in
the case of hemodiafiltration.
Conclusion: Hemodiafiltration has a beneficial effect on echocardiographic markers representing left ventricular
diastolic function. This could be attributed to the differences between the dynamics of volume removal and its
distribution among liquid compartments.
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Cardiovascular disorders remain the leading cause of
mortality in chronic kidney disease (CKD) patients [1].
Despite significant advances in renal replacement ther-
apy techniques, the cardiovascular mortality rate of these
dialyzed, accounts for more than 50% of the total mor-
tality rate and its frequency is 17 times higher compared
to the healthy population. Heart failure plays an import-
ant role in the unfavorable changes in mortality statis-
tics, which accounts for 64% at the time of initiation of
dialysis [2]. According to a recent study the median sur-
vival rate of 62 months among hemodialyzed patients
decreased to 36 months when heart failure was present* Correspondence: balla@internal.med.unideb.hu
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reproduction in any medium, provided the or[3]. The most common causes of heart failure in patients
with chronic kidney disease are advanced age, female
sex, hypertension, diabetes mellitus and atherosclerosis,
ischemic and structural heart disease. Renoparenchymal
hypertension is also an important factor, the frequency
of which, in patients receiving renal replacement ther-
apy, is estimated to be 89% [4]. The adaptive mecha-
nisms induced by the nephrons’ hyperfiltration, and the
harmful effects of persistent high blood pressure caused
by hypervolemia, have a major effect in the development
of left ventricular hypertrophy, which can also lead to
ventricular filling disorder. Furthermore, endothelial dys-
function plays an important role in the genesis of ath-
erosclerosis and hypertension in this group of patients.
Nitric oxide (NO) and the competitive inhibitor of nitric
oxide synthase - asymmetric dimethylarginin (ADMA) -
are known to be the key mediators in the regulation oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hanced formation of oxygen-derived free radicals were
shown to be present in patients on chronic hemodialysis
[5]. It is important to note that based on the severity of
diastolic heart function, patients may be relatively asymp-
tomatic. Nevertheless, regardless of clinical manifestation,
diastolic heart failure is an independent risk factor for
cardiovascular mortality in both symptomatic and asymp-
tomatic patients. Furthermore, diastolic dysfunction is an
important underlying factor in the development of atrial
fibrillation [6] and the pathomechanism is postulated
to be due to increased atrial volume load. Evidence sug-
gests that the mortality rate in patients participating in
hemodiafiltration programs is 35% lower than in those
receiving conventional hemodialysis [7]. Whereas conven-
tional treatment eliminates uremic toxins, depending on
their molecular weights, by diffusion, hemodiafiltration
also eliminates the medium molecular weight toxic po-
lypeptides (characterized by β-2 microglobulin) by con-
vective transport [8]. Whether hemodiafiltration and
conventional hemodialysis affect the left ventricular dia-
stolic function and vascular tone mediators differently is
not yet clear. Therefore, the extent of favorable mortality
rates in hemodiafiltration cases that may be attributed to
the diastolic function of the myocardium and the changes
in intracardiac pressure relations remains to be elucidated.
Methods
The statistical analysis was carried out with the help of the
SAS 8.2 for Windows software. The variations of the in-
vestigated parameters over time and the difference be-
tween the two modalities were investigated by using
repeated measures ANOVA. The correlation between the
parameters was analyzed by using the Pearson’s test when
the distribution was normal and by Spearman’s rank test
in the case of not normal distribution. Throughout the
analysis the p < 0.05 probability level was considered sta-
tistically significant. Data is presented as mean ± SD. The
examination results of thirty non-diabetic patients, with
end stage renal failure were studied (18 males, 12 females,
mean age 60 ± 13.6 years). At the time of selecting patients
for the study the mean time of renal replacement therapy
was 93.13 ± 70.09 months. Firstly, we collected and ana-
lyzed the data from the patients while they received
hemodiafiltration, and then from the same patients during
treatment with conventional hemodialysis for at least three
months. This was followed, at the time of the regular
hemodialysis, by further data collection and investigation.
Exclusion criteria were: any impulse generation or con-
duction disease which could affect echocardiographic
findings, or makes it impossible to measure certain echo-
cardiographic parameters. Thus, atrial fibrillation, where
no atrial contraction appears and A wave cannot be
detected during Doppler examination was an exclusioncriterion. In the case of atrial flutter the evaluation of
late diastolic transmitral velocity may not be easy to
measure, so patients with this type of arrhythmia were
also excluded. Furthermore, patients with amyloidosis,
sarcoidosis, carcinoid, hemochromatosis, and pericardial
constriction were not involved in the study, also patients
with pseudonormalization pattern were excluded. Patients
were included who were suffering from end stage kidney
disease (Stage 5) participating in regular hemodialysis pro-
gram in our center, and were willing to give their informed
consent to take part in the study. The chronic kidney dis-
ease of the studied population was caused by the follow-
ing: chronic glomerulonephritis (n = 5), hypertensive
and vascular nephropathy (n = 12), chronic pyeloneph-
ritis (n = 1), polycystic kidney disease (n = 2), analgesic ne-
phropathy (n = 3), renal agenesis (n = 1), systemic lupus
erythematosus (n = 2), and vasculitis (n = 4). Ninety per-
cent of the patients suffered from hypertension (arterial
blood pressure requiring antihypertensive therapy > 140/
90 mmHg), 16.7% had hypercholesterolemia (serum chol-
esterol >5.2 mmol/L) and 10% had ischemic heart disease
as shown by stress test. The patients – after receiving de-
tailed information about the trial – confirmed, in writing,
their will to participate in the study, and the Ethics Com-
mittee of the University of Debrecen approved the study
protocol. All procedures and treatments used on the study
group were part of standard care. Before and after the
renal replacement therapy transthoracic echocardiography
investigations (M-mode, 2 D) were performed with a
pulsed, and a continuous wave and tissue Doppler tech-
nique (Philips ATL HDI 5000 imaging system with a
3.5 MHz transducer). During the examinations the left
atrium’s cross diameter was measured from the paraster-
nal long-axis view, then, based on an apical four-chamber
view, the Simpson’s method was used to determine the left
ventricular ejection fraction. Using the Devereux-Reichek
formula the left ventricular mass index was calculated
({1.04x[(end-diastolic diameter of the left ventricle +
interventricular septum thickness + the posterior wall
thickness of the left ventricle)3-end-diastolic diameter of
the left ventricle3] -14}/height). The early diastolic trans-
mitral peak flow velocity (E) was determined from the ap-
ical four-chamber view with the help of a pulsed-wave
Doppler, and the peak flow velocity in the late diastolic
period during the atrial contraction (A) was also
determined. The time between the beginning and the end
of the E-wave deceleration slope was defined as deceler-
ation time (DT). Using Tissue Doppler Imaging (TDI) we
evaluated the early diastolic velocity of the septal mitral
annulus (Ea) from the apical approach. In order to esti-
mate the left ventricular filling pressure we calculated the
ratio of the E and Ea (E/Ea). First degree (mild) diastolic
dysfunction (DD) was defined as: E/A < 0.8, E/Ea < 8,
DT > 200 msec and second degree (medium) DD as: 0.8 <
Figure 1 Changes in left atrial cross diameter during the
sessions. A significant decrease in left atrial cross diameter occurred
during hemodiafiltration (p < 0.05), but the change did not prove to
be significant in the case of hemodialysis. HD: hemodialysis, HDF:
hemodiafiltration (*p < 0.001).
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criteria for third degree (severe) DD were: E/A > 2, E/Ea >
13, DT < 160 msec. At the time of randomization 7 of our
patients belonged to the severe group, 15 belonged to the
medium, and 8 to the mild group. In order to differentiate
between the normal and pseudonormal pattern, where
E/A ratio was proved to be normal (between 1–1.5) and
deceleration time was found to be above 140 msec, the
possible pseudonormalization was evaluated with the
measurement of E/Ea ratio, furthermore Valsalva maneu-
ver was performed. Patients with pseudonormalization
(relaxation pattern occurring during Valsalva maneuver
and E/Ea > 10) were not involved in the study. The diam-
eter of the inferior vena cava was measured from the sub-
costal view. Hemodialysis and hemodiafiltration were
performed three times a week during 4-hour long sessions
with Fresenius 4008 S and H devices (Fresenius Medical
Care, Bad Homburg, Germany), with Fx60 and Fx80
high-flux polysulfone dialysis capillaries (Fresenius). Dur-
ing hemodiafiltration 15.16 ± 5 liters of ultrafiltrate was
removed. The substitution fluid was prepared on-line
from dialysis solution through a set of two membranes to
purify it before infusing it directly into the blood line.
The replacement solution was manufactured on-line
from ultrapure water and consisted of 138 mmol/L so-
dium, 2 or 3 mmol/L potassium (in 13 cases 2 mmol/l in
17 cases 3 mmol/l), 1.5 mmol/L calcium, 0.5 mmol/L
magnesium, and 1 g/L glucose. The blood flow was 338 ±
11.6 ml/min and did not differ significantly during the
respective procedures (p < 0.05). The bicarbonate dialysis
solution contained 138 mmol/L sodium, 2 or 3 mmol/L
potassium (the same as the substitution solution), 1.5
mmol/L calcium, 0.5 mmol/L magnesium, and 1 g/L glu-
cose. During the treatment no drugs other than isotonic
sodium chloride and sodium heparin solutions were ad-
ministered. The previous drug therapy (digitalis, nitrates,
beta-blockers and calcium channel blockers, angiotensin
converting enzyme inhibitors, and angiotensin receptor
blockers) remained unchanged. The arterial blood pres-
sure was monitored non-invasively. In order to monitor
the heart rhythm and to analyze the RR cycle length
characterizing the heart frequency, five conventional 12-
lead electrocardiograms were carried out in each case: at
the beginning of the treatment, in the 15th, 30th, and the
240th minutes, and finally two hours after the treatment.
The ECG results were recorded by a 12-channel ECG
device at 25 mm/sec recording speed (Hewlett Packard
Page Writer 200i), and during the recordings the pa-
tients were in the supine position, breathing freely, and
were not talking. Nitric oxide concentration of the
serum was determined by the modified method of
Navarro-Gonzalez and ADMA concentrations in the
plasma were measured using an enzyme-linked im-
munosorbent assay (ELISA).Results
A significant decrease in left atrial cross diameter (p < 0.001)
occurred during hemodiafiltration which was not observed
in the case of hemodialysis (p = 0.11) (Figure 1). Echocar-
diography revealed that E and E/Ea decreased in both
renal replacement modalities (p < 0.001), however, no sta-
tistically significant difference was found between the two
renal replacement methods (p = 0.37). Regarding E/Ea
measured before the beginning of the sessions we did not
find statistically significant differences either (12.56 ± 3.56
vs. 11.65 ± 4.49, p = 0.14). E/A ratio’s significant decrease
was observed only during hemodiafiltration (p < 0.001).
(Table 1). The early transmitral flow velocity (E) character-
izing the early diastolic filling showed a significantly
pronounced decrease in the case of hemodiafiltration
(p < 0.001). In the case of hemodialysis E (p = 0.02) and
E/A (p = 0.021), and in the case of hemodiafiltration E
(p = 0.036) values positively correlated with changes in
body weight, however regarding E/Ea and body weight a
significant correlation was observed only in the case of
hemodiafiltration (p =0.041) (Figure 2). Similar trends
were found between E/Ea and the left atrial diameter. Dur-
ing hemodiafiltration the decreasing atrial diameter sig-
nificantly correlated with the decrease in E/Ea (p = 0.013),
while such a correlation was not observed during
hemodialysis (p = 0.15) (Figure 3). Moreover, the starting
diameter of the inferior vena cava showed a significant
correlation with the E/Ea decrease but only in the case of
hemodiafiltration (p = 0.009). The pre- and post-treatment
left ventricular ejection fraction, left ventricular mass
index, left ventricular end-systolic and end-diastolic diam-
eters did not change significantly, and none of these pa-
rameters showed a statistically significant correlation
Table 1 The echocardiographic parameters measured during the study
HD HDF
Before treatment After treatment Before treatment After treatment
E (cm/s) 103.4 ± 26.5 77.9 ± 22.6* 106 ± 26.5 72 ± 22*
A (cm/s) 92.2 ± 29.7 90.2 ± 26.2 95 ± 31 91.6 ± 22.8
Ea (cm/s) 8.6 ± 2.15 8.5 ± 1.95 12.4 ± 13.2 9.1 ± 2.25
E/A 1.37 ± 1.27 0.97 ± 0.63 1.2 ± 0.46 0.83 ± 0.34*
E/Ea 12.6 ± 3.55 9.88 ± 4.6* 11,65 ± 4.5 8,43 ± 4.46*
LA (mm) 45.4 ± 6.5 43.4 ± 6 45.1 ± 5,25 40.8 ± 5.8*
EF (%) 56.6 ± 9.2 56 ± 7.7 56,5 ± 8.7 54.6 ± 6.8
LVMI 203 ± 68.6 185 ± 63.7 180 ± 62.2 177.4 ± 64.7
LVESD (mm) 32.1 ± 7.2 31.6 ± 7.3 30.7 ± 5.55 30.6 ± 5.4
LVEDD (mm) 48.9 ± 7.8 47.5 ± 7.8 46.7 ± 6.6 45.8 ± 6.9
VCI (mm) 18.7 ± 2.8 16.2 ± 2.6* 19.7 ± 3 15.1 ± 2.8*
E and E/Ea decreased in both renal replacement modalities (p < 0.001), but E/A ratio’s significant decrease was observed only during hemodiafiltration.
HD: hemodialysis, HDF: hemodiafiltration, LA: left atrial cross diameter, EF: left ventricular ejection fraction, LVMI: left ventricular mass index, LVESD: left ventricular
end systolic diameter, LVEDD: left ventricular end diastolic diameter, VCI: inferior vena cava diameter (*p < 0.05).
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the ECG reading increased from the baseline after 30 -
minutes, which represents a decrease in the ventricular
rate (p = 0.027). During the conventional hemodialysis a
gradual decrease in the RR cycle length was observed,
which, by the end of treatment had reached a significant
level compared to the baseline (p = 0.024). Atrial fibrilla-
tion and malignant ventricular arrhythmias (ventricular
tachycardia and ventricular fibrillation) were not observed
in any of the treatments.
Regarding blood pressure during both modalities a
rapid decrease occurred after the initiation of the ses-
sions, which, compared to baseline, reached a significant
decrease after 15 minutes (p < 0.001). While the systolicFigure 2 The correlation between the changes in body weight and E/
A significant correlation was observed only in the case of hemodiafiltrationand the diastolic values were higher even at the initial
stages of the treatment in the hemodiafiltration group,
this trend had no statistical significance. The systolic
blood pressure did not change significantly afterwards,
however, there was an increase in diastolic values. Dur-
ing both renal replacement therapies, there were no dif-
ferences between the two modalities with respect to
body weight and body mass index (BMI). The change in
body weight was determined separately by gender, and it
can be concluded that in both cases a significant reduc-
tion occurred (p < 0.001). During hemodiafiltration and
conventional hemodialysis both NO and ADMA concen-
trations were observed to decrease significantly two
hours after completion of the treatments (p < 0.001)Ea ratio in the case of the two renal replacement modalities.
. HD: hemodialysis, HDF: hemodiafiltration (*p = 0.041).
Figure 3 The correlation between the left atrial cross diameter
and the decrease in E/Ea ratio during hemodiafiltration. The
decreasing atrial diameter was significantly correlated with the
decrease in E/Ea. ΔLAD: changes in the left atrial cross
diameter (*p = 0.013).
Figure 4 Correlation between the change in nitric oxide
concentration (ΔNO) and the decrease in the ratio between
transmitral peak flow velocity and late diastolic transmitral
velocity (ΔE/A) during hemodiafiltration. NO concentration
showed a positive correlation with the ratio between the early and
the late diastolic flow velocities (E/A) (*p = 0.011).
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sociated with modulation in NO concentration that
showed a positive correlation with the late diastolic
transmitral flow velocity (A) (p = 0.02) and the ratio be-
tween the early and the late diastolic flow velocities (E/A)
(p = 0.011) (Figure 4). Similar significant correlations were
not observed during hemodialysis. Furthermore, ADMA
level changes did not correlate significantly with the stud-
ied echocardiographic parameters.
Discussion
The mortality rate of patients participating in hemo-
diafiltration programs is 35% lower than those receiving
conventional hemodialysis that may be attributed to mul-
tiple factors [9]. For instance, it has been demonstrated
that in the case of hemodiafiltration the clearance of
small- and medium- molecular weight substances (urea,
creatinine, phosphate, beta-2 microglobulin, comple-
ment, leptin, cytokines, and homocysteine) was signifi-
cantly higher compared to conventional hemodialysis
[10-13]. Additionally, utilization of high-flux membranes
enhances biocompatibility and more importantly, the
concentration of acute phase proteins and inflammatory
mediators (C-reactive protein, interleukin-1, interleukin-6,
rheumatoid factor) do not rise during the treatment, or
thereafter. By reducing the beta-2 microglobulin concen-
trations observed during hemodiafiltration, the incidenceTable 2 Nitric oxide (NO) and asymmetric dimethylarginine (A
HD
Before treatment After trea
NO(μmol/L) 30.3 ± .76 12.23 ±
ADMA(μmol/L) 0.69 ± 0.2 0.55 ± 0
During hemodiafiltration and conventional hemodialysis both NO and ADMA conce
of the treatments (*p < 0.001).
HD: hemodialysis, HDF: haemodiafiltration.of amyloidosis can be reduced by approximately 50%
[14-18]. Furthermore, by utilizing a high-flux dialysis
membrane and an ultrasterile solution oxidative stress can
be significantly mitigated which is directly associated with
improvements in lipid profile [19,20]. On the other
hand, NO (a crucial regulator of vascular tone) concentra-
tions were shown to decrease during conventional
hemodialysis due to its increased degradation and dimin-
ished NO synthase activity, altered ADMA concentrations
and removal of NO metabolites [21]. Anemia is a common
finding in hemodialysis patients with a prevalence of more
than 80% and is frequently managed by erythropoietin
(EPO) administration. Hemodiafiltration has been shown
to improve anemia and it has been postulated that the
suppression of inflammatory reactions and elimination of
erythropoiesis inhibiting factors may contribute to the
positive changes in the frequency of anemia [22]. Previous
studies have shown that long-term uremic and hypovol-
emic status adversely affect left ventricular function [23].
The basis for that are the increased pre-, afterload, emer-
gence of hypertension, left ventricular hypertrophy, coron-
ary reserve lowering effect, and development of left
ventricular systolic and diastolic dysfunction. Although
the ventricular hypertrophy can be considered as an adap-
tive physiological response, it can result in myocyte-
capillary mismatch and subsequent myocardial ischemia,
fibrosis, as well as myocardial calcification [24]. BesidesDMA) concentrations measured during the study
HDF
tment Before treatment After treatment
5.7* 29.4 ± 18.25 11.55 ± 5.54*
.16* 0.64 ± 0.18 0.59 ± 0.15*
ntrations were observed to decrease significantly two hours after completion
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that the patients receiving hemodiafiltration for their renal
diseases were able to enjoy benefits resulting from the
slower progression of the cardiac target organ damage as
shown by Ohtake et al. [25]. Based on our results it can be
stated that hemodiafiltration – even though there was no
difference between the two modalities in terms of volume
removal – decreased left atrial volume more effectively.
While hemodiafiltration did not bring better improvement
of E/Ea compared to hemodialysis, only in the case of
hemodiafiltration could we find a positive correlation be-
tween E/Ea (representing the left ventricular pressure
load) and body weight. The changes in the left atrial diam-
eter during hemodiafiltration were closely related to the
E/Ea decrease, whereas no such correlation was observed
during conventional hemodialysis. This finding can be
partly explained by the difference in tissue liquid distribu-
tion resulting from the benefits of the convective trans-
port, which is the basis of hemodiafiltration. A degree of
similarity between the volume removals might be indi-
cated by the kinetics in the changes of blood pressure, but
the systolic and diastolic data showed a non-significant
difference even at the start of the treatment, which may
affect the value of a comparative study. The decrease in
NO and ADMA concentrations in both modalities might
indicate similar mechanisms in the metabolism of vascular
tone mediators. In contrast, significant correlations be-
tween NO and transmitral flow velocities (A and E/A)
were observed only in the case of hemodiafiltration, which
might attract attention to its beneficial effect on intracar-
diac pressure and left ventricular diastolic function. The
analysis concerning the changes observed in the heart rate
suggests a difference in the dynamics of volume removal
in the case of the two modalities. Although atrial and ven-
tricular arrhythmias were not observed in our study, the
atrial and ventricular pressure load reduction during
hemodiafiltration, through reducing the propensity for
cardiac arrhythmias and arrhythmia vulnerability, can
result in a favorable arrhythmia risk development. Our
results show that the clinical and echocardiographic pa-
rameters demonstrated different data on several points,
and that two renal replacement methods influenced the
preservation of the left ventricular diastolic function
differently. This might be the result of the more bal-
anced, but increased intracardiac and intravascular vol-
ume reduction, the more effective balancing of the
osmotically active agents’ concentration in the serum,
which results in a more effective decrease in the left
ventricular load pressure and the atrial diameter. An-
other plausible explanation is the potent antioxidant
and anti-inflammatory effect, and also the more
efficient removal of the small-and medium-molecular-
weight materials and uremic toxins that could be ob-
served during hemodiafiltration.Conclusions
This study investigated the differences between conven-
tional hemodialysis and hemodiafiltration in the context of
cardiovascular parameters. The strength of these findings
stems from the fact that the same patients were examined
by two different therapeutic modalities. Additionally, the
obtained results did not show any correlation with the
etiology of chronic kidney disease. Our results suggest
that there were significant disparities between the studied
echocardiographic markers and the clinical parameters
representing the left ventricular diastolic function in the
case of the two renal replacement modalities, despite the
fact that there was no significant difference between the
volume removals. These findings could be explained by
the more efficient detoxification which occurs because of
the convective transport present during hemodiafil-
tration, and also the differences between the dynamics of
volume removal and its distribution among the liquid
areas. Further studies are needed to analyze the impact
of hemodiafiltration on ventricular functions in larger
clinical trials.
Study limitations
The number of the studied patients is relatively small,
however all patients suitable for clinical investigations
were enrolled from our center. A larger study population
would help to clarify the role of different renal replace-
ment therapies on left ventricular diastolic function. The
determination of long term effects of hemodiafiltration
on cardiac function was not possible during the present
study, so further investigations are needed to get a
clearer picture on this issue. Our results apply only to
our selected group of patients without rhythm abnor-
malities and a low frequency of coronary artery disease.
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